Plasmodium vivax Duffy binding protein ligand domain (DBPII) is a leading vivax vaccine candidate based upon its relative importance for parasite survival during the disease-causing blood stage. However, DBPII is naturally weakly immunogenic and induces strain-specific immunity. Our approach to solve the problem strain immunity is to design a vaccine that focuses antibody responses onto conserved B-cell epitopes in functional regions within DBPII that are proven targets of protective immunity. In a proof-of-concept study, we demonstrated that an engineered DBPII immunogen lacking the dominant variant B-cell epitope retained good immunogenicity and induced more broadly inhibitory antibodies (BIAbs). The results for the DBPII- engineered vaccine is promising and the next critical step will be to determine the requirements to induce long-lived antibody and memory B-cell (MBCs) responses targeting conserved neutralizing epitopes. The overall goal of this program is to design a vaccination strategy to induce the distinct subpopulations of B- cells that are expanded in people with protective immunity to vivax malaria. Our hypothesis is people able to produce broadly naturally acquired DBPII BIAbs (elite responders) mount an efficient and long-term DBPII- specific memory B-cells (MBCs) and this can be replicated by vaccination. We will phenotypically and functionally characterize B cell sub-sets in immune individuals, to optimize the design of new DBPII vaccine that can induce MBCs cells with specificity for different DBPII. For that, we will take advantage of Brazilian cross-sectional and cohort studies, where different profiles of DBPII responders were identified, including persistent responders with strain-transcending DBPII-BIABs. DBPII is expected to be an important component of a multi-stage, multi-valent vaccine to protect against vivax malaria. The proposal builds on a solid and successful collaboration established between the Brazilian and US collaborators, combining strengths parasitology, immunology, and structural biology to optimize DBPII as an effective vaccine against vivax malaria.

Public Health Relevance

Malaria is a significant global health problem and Plasmodium vivax is the major cause of non-African malaria, causing 16 million cases of clinical malaria in 2013 at an estimated cost of $1.4 - $4 billion per year. Widespread drug resistance, the relapsing nature of P. vivax, and emerging virulent forms of P. vivax emphasizes the critical need for development of a vaccine against P. vivax. Our overall goal is to develop a vaccine to eliminate vivax malaria as a major health problem.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI064478-13
Application #
9920658
Study Section
Vaccines Against Microbial Diseases Study Section (VMD)
Program Officer
MO, Annie X Y
Project Start
2006-08-01
Project End
2024-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
13
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of South Florida
Department
Other Health Professions
Type
Schools of Public Health
DUNS #
069687242
City
Tampa
State
FL
Country
United States
Zip Code
33617
Armistead, Jennifer S; Adams, John H (2018) Advancing Research Models and Technologies to Overcome Biological Barriers to Plasmodium vivax Control. Trends Parasitol 34:114-126
Roth, Alison; Maher, Steven P; Conway, Amy J et al. (2018) A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum. Nat Commun 9:1837
Adams, John H; Mueller, Ivo (2017) The Biology of Plasmodium vivax. Cold Spring Harb Perspect Med 7:
Ovchynnikova, Elina; Aglialoro, Francesca; Bentlage, Arthur E H et al. (2017) DARC extracellular domain remodeling in maturating reticulocytes explains Plasmodium vivax tropism. Blood 130:1441-1444
Ntumngia, Francis B; Pires, Camilla V; Barnes, Samantha J et al. (2017) An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies. Sci Rep 7:13779
Shaw-Saliba, Kathryn; Thomson-Luque, Richard; Obaldía 3rd, Nicanor et al. (2016) Insights into an Optimization of Plasmodium vivax Sal-1 In Vitro Culture: The Aotus Primate Model. PLoS Negl Trop Dis 10:e0004870
Nicolete, Vanessa C; Frischmann, Sarah; Barbosa, Susana et al. (2016) Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians. J Infect Dis 214:1539-1546
Wongkidakarn, Sudarat; McHenry, Amy M; Sattabongkot, Jetsumon et al. (2016) Strain-Transcending Inhibitory Antibodies against Homologous and Heterologous Strains of Duffy Binding Protein region II. PLoS One 11:e0154577
Ntumngia, Francis B; Thomson-Luque, Richard; Pires, Camilla V et al. (2016) The role of the human Duffy antigen receptor for chemokines in malaria susceptibility: current opinions and future treatment prospects. J Receptor Ligand Channel Res 9:1-11
Salinas, Nichole D; Tolia, Niraj H (2016) Red cell receptors as access points for malaria infection. Curr Opin Hematol 23:215-23

Showing the most recent 10 out of 38 publications